Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.

Hepatology (Baltimore, Md.) - 1 Aug 2022

Indolfi Guiseppe, Kelly Deirdre, Nebbia Gabriella, Iorio Raffaele, Mania Anna, Giacomet Vania, Szenborn Leszek, Shao Jiang, Sang Yue Mun, Hsueh Chia-Hsiang, Parhy Bandita, Kersey Kathryn, Mangia Alessandra, Pawlowska Malgorzata, Bansal Sanjay

Abstract excerpt

BACKGROUND AND AIMS: Sofosbuvir-velpatasvir-voxilaprevir is a pangenotypic regimen for chronic HCV infection. In the USA and Europe, sofosbuvir-velpatasvir-voxilaprevir once daily for 12 weeks is indicated for adults who previously received an HCV NS5A inhibitor. In Europe, sofosbuvir-velpatasvir-voxilaprevir is also indicated in the absence of prior HCV direct-acting antiviral (DAA) therapy as an 8-week or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Heterocyclic Compounds, 4 or More Rings

Share to Lactams, Macrocyclic

Share to Quinoxalines

Share to Sofosbuvir

Share to Sustained Virologic Response

Source

Identifiers

PMID: 35112372
DOI: 10.1002/hep.32393

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.PMID 35112372Read ↗

Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.Semantic proximity Read ↗

Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infectionSemantic proximity Read ↗

Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older.Semantic proximity Read ↗

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C-Results of the PANDAA-PED study.Semantic proximity Read ↗

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.Semantic proximity Read ↗

Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.Semantic proximity Read ↗

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 InfectionSemantic proximity Read ↗

Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.Semantic proximity Read ↗

Treatment of hepatitis C in children and adolescents: how far have we reached?Semantic proximity Read ↗

Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.